Completion of the First Interventional Phase-II Trial in the Innovative Medicines Initiative's New Drugs 4 Bad Bugs Programme; Results from the SAATELLITE trial to be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and American Thoracic Society (ATS) meetings by the COMBACTE-NET Consortium
In: PR Newswire Europe, 2019-04-11, S. 4
Zeitungsartikel
Zugriff:
UTRECHT, Netherlands, April 11, 2019 /PRNewswire/ --The Innovative Medicines Initiative (IMI)-funded COMBACTE-NET (Combatting Bacterial Resistance in Europe) consortium has completed the SAATELLITE study, a phase II trial of suvratoxumab, a novel monoclonal antibody (mAb) targeting Staphylococcusaureus. The trial, sponsored by AstraZeneca and part of the Innovative Medicines Initiative (IMI) programme, assessed the novel mAb's ability to prevent Staphylococcus aureus Ventilator-Associated Pneumonia (VAP) in mechanically ventilated intensive care unit (ICU) patients...
Titel: |
Completion of the First Interventional Phase-II Trial in the Innovative Medicines Initiative's New Drugs 4 Bad Bugs Programme; Results from the SAATELLITE trial to be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and American Thoracic Society (ATS) meetings by the COMBACTE-NET Consortium
|
---|---|
Zeitschrift: | PR Newswire Europe, 2019-04-11, S. 4 |
Veröffentlichung: | 2019 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|